VIRIDIAN THERAPEUTICS INC (VRDN)
US92790C1045 - Common Stock
We assign a fundamental rating of 3 out of 10 to VRDN. VRDN was compared to 568 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VRDN had negative earnings in the past year.
In the past year VRDN has reported a negative cash flow from operations.
In the past 5 years VRDN always reported negative net income.
In the past 5 years VRDN always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -33.31%, VRDN is in the better half of the industry, outperforming 64.78% of the companies in the same industry.
VRDN has a Return On Equity of -36.34%. This is in the better half of the industry: VRDN outperforms 75.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.31% | ||
| ROE | -36.34% | ||
| ROIC | N/A |
ROA(3y)-39.1%
ROA(5y)-67.96%
ROE(3y)-42.99%
ROE(5y)-97.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VRDN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
Compared to 5 years ago, VRDN has more shares outstanding
VRDN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 13.62 indicates that VRDN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.62, VRDN belongs to the top of the industry, outperforming 89.03% of the companies in the same industry.
VRDN has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of VRDN (0.03) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.62 |
ROIC/WACCN/A
WACC11.77%
2.3 Liquidity
A Current Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.55, VRDN belongs to the top of the industry, outperforming 94.16% of the companies in the same industry.
A Quick Ratio of 18.55 indicates that VRDN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 18.55, VRDN belongs to the best of the industry, outperforming 94.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.55 | ||
| Quick Ratio | 18.55 |
3. Growth
3.1 Past
VRDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.49%, which is quite good.
The Revenue for VRDN has decreased by -13.71% in the past year. This is quite bad
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -48.16% on average per year.
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.5%
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y-48.16%
Sales Q2Q%19.44%
3.2 Future
VRDN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.99% yearly.
Based on estimates for the next years, VRDN will show a very strong growth in Revenue. The Revenue will grow by 346.05% on average per year.
EPS Next Y23.69%
EPS Next 2Y9.51%
EPS Next 3Y7.8%
EPS Next 5Y15.99%
Revenue Next Year-13.46%
Revenue Next 2Y-18.46%
Revenue Next 3Y365.68%
Revenue Next 5Y346.05%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRDN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.51%
EPS Next 3Y7.8%
5. Dividend
5.1 Amount
No dividends for VRDN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRIDIAN THERAPEUTICS INC
NASDAQ:VRDN (12/18/2024, 1:37:11 PM)
19.83
-0.99 (-4.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.57B
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.31% | ||
| ROE | -36.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 18.55 | ||
| Quick Ratio | 18.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y23.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-13.71%
Revenue growth 3Y-33.13%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y